GTH

Genetron Holdings Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.52
-0.03
-0.28%
Opening 13:08 10/22 EDT
OPEN
11.51
PREV CLOSE
11.55
HIGH
11.56
LOW
11.48
VOLUME
3.27K
TURNOVER
--
52 WEEK HIGH
17.71
52 WEEK LOW
9.03
MARKET CAP
1.02B
P/E (TTM)
-2.5529
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Genetron Health Enters Exclusive Global Licensing Agreement with ImmuQuad Biotechnologies to Develop and Commercialize Minimal Residual Disease Assays in Hematologic Cancer
Genetron Holdings Limited (“Genetron Health” or the “Company”) (NASDAQ:GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer
Benzinga · 7h ago
Mid-Afternoon Market Update: Dow Jumps 350 Points; Iterum Therapeutics Shares Spike Higher
Toward the end of trading Wednesday, the Dow traded up 1.28% to 27,804 while the NASDAQ rose 0.83% to 11177.49. The S&P also rose, gaining 0.92% to 3,366.11.
Benzinga · 09/30 19:55
OAS, OMP, CTIC and NNDM among midday movers
Gainers: Iterum Therapeutics (ITRM) +146%.CTI BioPharma (CTIC) +110%.CynergisTek (CTEK) +69%.Nano Dimension (NNDM) +38%.Wanda Sports Group (WSG) +28%.Genetron (GTH) +24%.Allena Pharmaceuticals (ALNA) +20%.Sky Solar (SKYS) +19%.RAPT Therapeutics (RAPT) +19%.Limbach Holdings (LMB) +16%.Losers: Aptorum
Seekingalpha · 09/30 16:43
CTI BioPharma, Genetron Holdings leads healthcare gainers, Aptorum Group, Adial Pharmaceuticals among major losers
Gainers: CTI BioPharma (CTIC) +99%, Genetron Holdings (GTH) +26%, Allena Pharmaceuticals (ALNA) +23%, Neurotrope (NTRP) +20%, Kaleido Biosciences (KLDO) +11%.Losers: Aptorum Group (APM) -41%, Adial Pharmaceuticals (ADIL) -21%, Avalon GloboCare (AVCO) -15%, Galectin Therapeutics (GALT) -15%, Windtree Therapeutics (WINT) -13%.
Seekingalpha · 09/30 15:00
Genetron Health +8% on Breakthrough Device tag for HCCscreen
Genetron Holdings' (GTH) blood-based next-generation sequencing ((NGS)) test, HCCscreen, has been granted Breakthrough Device designation by the FDA.HCCscreen is intended for early detection of hepatocellular carcinoma in individuals who are designated
Seekingalpha · 09/30 12:23
Genetron Health Receives US FDA Breakthrough Device Designation For its Blood-Based NGS Test For Early Detection Of Hepatocellular Carcinoma
BEIJING and GAITHERSBURG, Md., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China
Benzinga · 09/30 12:13
Genetron: 3 Reasons To Stay Bullish On China's Early-Stage Cancer Screening
China has a considerably large gene pool, a decisive success factor in conducting prospective research in early-stage cancer studies. Local bureaucracy has the power to lead nationwide research.As the early cancer-screening technology matures, the commercial strategy at the current stage is more critical. In China's blue-ocean market, Genetron has the first-mover advantage in market deployment.GTH recently engaged in a national key cohort study at a scale of 10 thousand patients for prospective cancer research.Compared to pan-cancer detection developer Burning Rock, Genetron focuses on specific types and moves faster on business expansion.
Seekingalpha · 09/25 16:53
The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 24)
Benzinga · 09/25 11:37
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GTH. Analyze the recent business situations of Genetron Holdings Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GTH stock price target is 19.80 with a high estimate of 21.09 and a low estimate of 19.00.
EPS
Institutional Holdings
Institutions: 43
Institutional Holdings: 19.75M
% Owned: 22.36%
Shares Outstanding: 88.36M
TypeInstitutionsShares
Increased
0
0
New
43
19.75M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GTH
Genetron Holdings Limited is a precision oncology company that specializes in cancer molecular profiling and harnesses technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive product and service portfolio that cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care. The Company operates its businesses primarily within the China market.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Genetron Holdings Ltd - ADR stock information, including NASDAQ:GTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GTH stock methods without spending real money on the virtual paper trading platform.